Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 117 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/31/2007 First Published: 4/1/1999


1.		Phase III Randomized Study of Cisplatin With or Without Monoclonal Antibody C225 in Patients With Metastatic and/or Recurrent Squamous Cell Cancer of the Head and Neck

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI				ECOG-E5397 E5397, NCT00003809

Last Modified: 5/3/2006 First Published: 2/1/2000


2.		Phase III Randomized Study of Radiotherapy With or Without Concurrent Cetuximab in Patients With Advanced Squamous Cell Carcinoma of the Oropharynx, Hypopharynx, or Larynx

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UAB-9901 IMCL-CP02-9815, NCI-G99-1657, NCT00004227

Last Modified: 6/15/2007 First Published: 12/23/2003


3.		Phase III Randomized Study of Gemcitabine With Versus Without Cetuximab as First-Line Therapy in Patients With Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Not specified				NCI				SWOG-S0205 S0205, NCT00075686, CALGB-S0205, CAN-NCIC-PAC1, PAC1

Last Modified: 11/17/2006 First Published: 1/23/2004


4.		Phase III Randomized Study of Fluorouracil and Leucovorin Calcium With Irinotecan or Oxaliplatin and With or Without Cetuximab in Patients With Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				CALGB-80203 CALGB-80203, NCT00077233


5.		Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				CA225006 NCT00063141


6.		Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				CA225014 NCT00061815

Last Modified: 6/20/2008 First Published: 2/20/2004


7.		Phase III Randomized Study of Cetuximab and Best Supportive Care Versus Best Supportive Care Alone in Patients With Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				16 and over				Other, Pharmaceutical / Industry				CAN-NCIC-CO17 AGITG-CAN-NCIC-CO17, BMS-CA225-025, IMCL-CAN-NCIC-CO17, NCT00079066, CO17


8.		Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				CA225-099 NCT00112294

Last Modified: 5/13/2008 First Published: 9/9/2005


9.		Phase III Randomized Study of Continuous Combination Chemotherapy Comprising Oxaliplatin, Leucovorin Calcium, and Fluorouracil (OxMdG) or Oxaliplatin and Capecitabine (XELOX) With Versus Without Cetuximab Versus Intermittent Combination Chemotherapy With OxMdG or XELOX as First-Line Therapy in Patients with Metastatic Colorectal Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Other				UKM-MRC-COIN-CR10 EU-20516, NCT00182715, EUDRACT-2004-002951-16, ISRCTN27286448, COIN


10.		Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				EMR 62202-002 NCT00122460

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute